The Independent Director of Acerus Pharmaceuticals Corporation (TSE:ASP), Stephen Gregory, Just Bought 52% More Shares

Whilst it may not be a huge deal, we thought it was good to see that the Acerus Pharmaceuticals Corporation (TSE:ASP) Independent Director, Stephen Gregory, recently bought CA$78k worth of stock, for CA$0.025 per share. While that isn't the hugest buy, it actually boosted their shareholding by 52%, which is good to see.

Check out our latest analysis for Acerus Pharmaceuticals

The Last 12 Months Of Insider Transactions At Acerus Pharmaceuticals

Notably, that recent purchase by Stephen Gregory is the biggest insider purchase of Acerus Pharmaceuticals shares that we've seen in the last year. Even though the purchase was made at a significantly lower price than the recent price (CA$0.035), we still think insider buying is a positive. While it does suggest insiders consider the stock undervalued at lower prices, this transaction doesn't tell us much about what they think of current prices.

In the last twelve months Acerus Pharmaceuticals insiders were buying shares, but not selling. The chart below shows insider transactions (by companies and individuals) over the last year. If you want to know exactly who sold, for how much, and when, simply click on the graph below!

Acerus Pharmaceuticals is not the only stock that insiders are buying. For those who like to find winning investments this free list of growing companies with recent insider purchasing, could be just the ticket.

Insider Ownership

For a common shareholder, it is worth checking how many shares are held by company insiders. We usually like to see fairly high levels of insider ownership. Our data suggests Acerus Pharmaceuticals insiders own 1.9% of the company, worth about CA$996k. I generally like to see higher levels of ownership.

What Might The Insider Transactions At Acerus Pharmaceuticals Tell Us?

It's certainly positive to see the recent insider purchases. We also take confidence from the longer term picture of insider transactions. But we don't feel the same about the fact the company is making losses. On this analysis the only slight negative we see is the fairly low (overall) insider ownership; their transactions suggest that they are quite positive on Acerus Pharmaceuticals stock. In addition to knowing about insider transactions going on, it's beneficial to identify the risks facing Acerus Pharmaceuticals. Our analysis shows 6 warning signs for Acerus Pharmaceuticals (3 are a bit concerning!) and we strongly recommend you look at these before investing.

But note: Acerus Pharmaceuticals may not be the best stock to buy. So take a peek at this free list of interesting companies with high ROE and low debt.

For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions, but not derivative transactions.

When trading Acerus Pharmaceuticals or any other investment, use the platform considered by many to be the Professional's Gateway to the Worlds Market, Interactive Brokers. You get the lowest-cost* trading on stocks, options, futures, forex, bonds and funds worldwide from a single integrated account. Promoted

This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
^*Interactive Brokers Rated Lowest Cost Broker by StockBrokers.com Annual Online Review 2020

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com.